Burykina O. Pharmacological rationale for utilization of a combined agent Glikverin at diabetes mellitus

In thesis the experimental rationale for composition and pharmacological study of a new combined agent Glikverin based on alpfa-glucosidase inhibitor voglibose and antioxidant quercetin were conducted. It is established that Glikverin has blood glucose lowering, antioxidant, hypolipidemic properties, has an ability to inhibit development of a postprandial hyperglycemia, improves sensibility of tissues to insulin action and increases their glucose tolerance. Indicated characteristics provide significant antidiabetic properties of Glikverin in dose of 50mg/kg in experimental models of insulin resistance, induced by dexamethasone and high sucrose diet and streptizotocin and alloxan diabetes in rats. In strength of pharmacological action Glikverin significantly prevails over its components and reference agent metformin. Glikverin belongs to a class of little toxic agents, does not increase motor activity of gastrointestinal system. Glikverin is a promising agent for further non-clinical and clinical investigation and for implementation in practical medicine as an agent for correction of insulin resistant conditions and for treatment of diabetes mellitus type 2 in mono therapy and in complex therapy with other hypoglycemic agents.